大基金二期减持思特威；中油资本拟增资昆仑资本丨公告精选

Group 1 - The major shareholder of Siwei has reduced its stake from 7.35% to 6.99% by selling 1.45 million shares [2] - Zhongyou Capital plans to invest 655 million yuan in Kunlun Capital for controlled nuclear fusion projects [2] - Rongchang Bio's drug Taitasip has received orphan drug designation from the EU for treating myasthenia gravis, providing various development supports [2] Group 2 - Dongxin Pinghe's stock has experienced significant volatility, with a focus on blockchain and digital currency technologies, but faces risks in new technology development [3] - Guoxin Technology has successfully tested its anti-quantum password card product and has sent samples to multiple clients for application development [3] Group 3 - Haizuo New Materials intends to acquire 80% of Kangningte and 100% of an engineering company for 186 million yuan [5] - Xinhang New Materials' controlling shareholder plans to transfer 3% of the company's shares [6] Group 4 - China Software has received approval from the CSRC for a specific issuance of A-shares [9] Group 5 - Xiamen Tungsten's new energy materials product sales increased by approximately 20.95% year-on-year from January to May [11] - Yongxi Electronics expects a revenue growth of 16.60% to 28.88% year-on-year in the first half of 2025 [11] - Tiande Yu anticipates a revenue increase of about 55.59% year-on-year in the first five months [11] - Jingyi Equipment expects a revenue increase of 36.54% to 42.48% year-on-year in the first half [11] - Dameng Data forecasts a revenue growth of 40.63% to 45.74% year-on-year in the first half [11]